Related Experiment Video
Updated: Jul 13, 2026
07:57
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures
Panayiotis Mavroidis1, Brigida Costa Ferreira, Chengyu Shi
1Department of Medical Radiation Physics, Karolinska Institutet and Stockholm University, Sweden.
Physics in Medicine and Biology
|August 1, 2007
Summary
This study compared helical tomotherapy (HT) and multi-leaf collimator (MLC)-based intensity-modulated radiotherapy (IMRT) for head and neck, lung, and prostate cancers. Radiobiological evaluation showed HT superior for head and neck, while MLC-IMRT excelled in lung and prostate cases.
Area of Science:
- Radiation Oncology
- Medical Physics
- Cancer Treatment
Background:
- Advanced radiation therapy technologies like intensity-modulated radiotherapy (IMRT) present challenges in treatment evaluation.
- Current methods often rely on dosimetric criteria, neglecting radiobiological parameters of tumors and normal tissues.
- Helical tomotherapy (HT) and multi-leaf collimator (MLC)-based IMRT are popular treatment delivery modes requiring effective evaluation.
Purpose of the Study:
- To compare the effectiveness of HT and MLC-based IMRT using a radiobiological evaluation method.
- To assess treatment plan suitability by incorporating biologically effective uniform dose (D) and complication-free tumour control probability (P(+)).
- To investigate treatment outcomes for head and neck, lung, and prostate cancers planned with HT and MLC-IMRT.
Main Methods:
- Developed HT and MLC-based IMRT plans for three cancer types (head and neck, lung, prostate).
- Utilized Philips Pinnacle 7.6 for MLC-IMRT and a dedicated tomotherapy station for HT plans.
- Applied a radiobiological evaluation using biologically effective uniform dose (D) and complication-free tumour control probability (P(+)) via P(+)-D diagrams.
Main Results:
- HT demonstrated superior P(+) for head and neck cancer (62.2% vs. 46.0% for MLC-IMRT).
- MLC-based IMRT showed better P(+) for lung (72.9% vs. 66.9% for HT) and prostate cancers (72.2% vs. 68.7% for HT).
- Allowing a higher complication risk (>5%) could increase complication-free tumor control by over 40%, 2%, and 30% for the respective cancer types.
Conclusions:
- Radiobiological evaluation, using P(+)-D diagrams, provides a more comprehensive assessment than traditional dosimetric criteria.
- The choice between HT and MLC-IMRT depends on the cancer type, with HT favoring head and neck and MLC-IMRT favoring lung and prostate.
- This approach aids in selecting optimal treatment plans by correlating delivered radiation with expected clinical outcomes, considering dose-response characteristics.
